Moria has acquired the Italian ophthalmic pharmaceutical company Alchimia, enhancing its product portfolio and market presence while capitalizing on the strong growth potential in the ophthalmic industry.

Target Company Overview

Moria, a historical firm established in the micro-surgery sector, specializes in the design and manufacturing of ophthalmic micro-surgical instruments and equipment for refractive surgery and corneal transplantation. Since 2019, Moria has been owned by Naxicap Partners, which has facilitated its growth and innovation in the industry.

As part of its expansion strategy, Moria has acquired the Italian company Alchimia, a Padua-based manufacturer of pharmaceutical products for ophthalmic surgery, including ophthalmic gels, dyes for anterior and posterior segments, ophthalmic gases, perfluorocarbons, and silicone oils. Alchimia also operates a human tissue bank specializing in eye tissues, thus enhancing Moria's product portfolio.

Industry Overview in Italy

The ophthalmic surgical market in Italy has been witnessing steady growth, driven by increasing awareness of eye health and advancements in surgical techniques and techn